A biopharmaceutical company focused on developing medicines for orphan pulmonary and fibrosis indications, with lead programs including LTI-03 for idiopathic pulmonary fibrosis and LTI-01 for loculated pleural effusion, along with pipeline candidates targeting cystic fibrosis and systemic fibrosis.